Clinical trial NCT06253559: Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria
Official title: Clinical and Pathological Characteristics of Women With Ovarian Cancers, A National, Retrospective Cross-Sectional Study in Syria During the War
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ovarian Cancer
Lead sponsor: Tishreen University
Sponsor class: OTHER
First posted: 2024-02-12
Enrollment: 531
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all women with ovarian cancer, with age ≥18 years,who have primary ovarian malignancy and underwent surgical or non-surgical treatment.

the data recorded from records of the Departments of Gynecology and Oncology at Tishreen University Hospital in Latakia, Al-Bairouni University Hospital in Damascus, and Ibn Rushd Hospital in Aleppo, which are the 3 major hospitals in Syria that admit and treat patients with ovarian cancer.

Brief summary: the goal of this observational study is to describe ovarian cancer epidemiology and characteristics in Syrian women, especially during the war to do more research in the future about the risk factors of ovarian cancer.

Detailed description: Ovarian cancer (OC) is the eighth most common cause of death worldwide, and current studies show that the death numbers caused by it will rise dramatically in the coming years. As the epidemiological features of the cancer may vary, studying these different characteristics can help us improve treatment outcomes and add preventive measures. In addition, giving special attention to these features in developing countries, or countries undergoing crisis, will help us understand the associated risk factors in these regions.

Eligibility criteria: Inclusion Criteria:

* female adult (age ≥18 years)
* primary ovarian malignancy

Exclusion Criteria:

* less than 18 years old
* women who have benign tumors or metastatic ovarian cancer.

Primary outcomes:
measure: age
timeFrame: jan 2017 - july 2021
measure: ovarian cancer grade
timeFrame: jan 2017 - july 2021
measure: histological type of ovarian cancer
timeFrame: jan 2017 - july 2021
measure: sideness of ovarian cancer
timeFrame: jan 2017 - july 2021
measure: Cancer Antigen-125
timeFrame: jan 2017 - july 2021
measure: Treatment
timeFrame: jan 2017 - july 2021
measure: symptoms of ovarian cancer
timeFrame: jan 2017 - july 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Latakia
country: Syrian Arab Republic
facility: Tishreen University
Study officials:
affiliation: Tishreen University
name: Apelian
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zheng G, Yu H, Kanerva A, Forsti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. PLoS One. 2018 Oct 3;13(10):e0205000. doi: 10.1371/journal.pone.0205000. eCollection 2018.
citation: Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjoholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20.
citation: Yuan R, Zhang C, Li Q, Ji M, He N. The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis. Gynecol Oncol. 2021 Sep;162(3):778-787. doi: 10.1016/j.ygyno.2021.06.008. Epub 2021 Jun 16.
citation: Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
citation: Shanmughapriya, S., Senthilkumar, G., Arun, S., Das, B. C., & Natarajaseenivasan, K. (2016). Risk factors for epithelial ovarian carcinoma in India: A case control study in low-incidence population. International Journal of Cancer Research, 12(1), 61-68. https://doi.org/10.3923/IJCR.2016.61.68
citation: Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.
citation: Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012 Mar;460(3):237-49. doi: 10.1007/s00428-012-1203-5. Epub 2012 Feb 10.
citation: Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol. 1991 Oct;43(1):9-23. doi: 10.1016/0090-8258(91)90003-n.
citation: Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30;11:287-299. doi: 10.2147/IJWH.S197604. eCollection 2019.
citation: Meena RK, Syed NA, Sheikh ZA, Guru FR, Mir MH, Banday SZ, Mp AK, Parveen S, Dar NA, Bhat GM. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. JCO Glob Oncol. 2022 Nov;8:e2200032. doi: 10.1200/GO.22.00032.
citation: McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7.
citation: Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):98-107.
citation: the World Cancer Research Fund (WCRF), worldwide cancer data., 2020; https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ )
citation: Lima MA, Dos Santos L, Turri JA, Nonogaki S, Buim M, Lima JF, de Jesus Viana Pinheiro J, Bueno de Toledo Osorio CA, Soares FA, Freitas VM. Prognostic Value of ADAMTS Proteases and Their Substrates in Epithelial Ovarian Cancer. Pathobiology. 2016;83(6):316-26. doi: 10.1159/000446244. Epub 2016 Jul 1.
citation: Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007 Jan;12(1):20-37. doi: 10.1634/theoncologist.12-1-20.
citation: Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020 Oct 28;17(10):e1003295. doi: 10.1371/journal.pmed.1003295. eCollection 2020 Oct.
citation: Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol. 2013 Apr;129(1):258-64. doi: 10.1016/j.ygyno.2012.12.016. Epub 2012 Dec 22.
citation: Arora T, Mullangi S, Vadakekut ES, Lekkala MR. Epithelial Ovarian Cancer. 2024 May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK567760/
citation: Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. BMC Cancer. 2018 Oct 25;18(1):1039. doi: 10.1186/s12885-018-4970-9.
citation: Andrews L, Mutch DG. Hereditary Ovarian Cancer and Risk Reduction. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:31-48. doi: 10.1016/j.bpobgyn.2016.10.017. Epub 2017 Jan 17.
citation: Zhang S, Cheng C, Lin Z, Xiao L, Su X, Zheng L, Mu Y, Liao M, Ouyang R, Li W, Ma J, Cai J, Liu L, Wang D, Zeng F, Liu J. The global burden and associated factors of ovarian cancer in 1990-2019: findings from the Global Burden of Disease Study 2019. BMC Public Health. 2022 Jul 30;22(1):1455. doi: 10.1186/s12889-022-13861-y.
citation: Saki S, Ali NR, Saki SS, AlRabeea ZS, AlRemeithi FN, Carrick FR, Abdulrahman M. Barriers to healthcare seeking, beliefs about ovarian cancer and the role of socio-economic position. A cross-sectional multilevel study in Dubai, a multicultural society. J Public Health Res. 2021 Mar 24;10(3):2073. doi: 10.4081/jphr.2021.2073.
citation: Ovarian cancer statistics | World Cancer Research Fund International. (n.d.). Retrieved May 19, 2023, from https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/
citation: Syria crisis . (n.d.). Retrieved May 19, 2023, from https://www.who.int/emergencies/situations/syria-crisis
citation: Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10. doi: 10.1002/1098-2388(200007/08)19:13.0.co;2-s.
citation: Gaona-Luviano P, Medina-Gaona LA, Magana-Perez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020 Aug;9(4):47. doi: 10.21037/cco-20-34. Epub 2020 Jun 30.
citation: Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
citation: Boussios S, Karathanasi A, Zakynthinakis-Kyriakou N, Tsiouris AK, Chatziantoniou AA, Kanellos FS, Tatsi K. Ovarian carcinosarcoma: Current developments and future perspectives. Crit Rev Oncol Hematol. 2019 Feb;134:46-55. doi: 10.1016/j.critrevonc.2018.12.006. Epub 2018 Dec 24.
citation: Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN, Kampan NC. New Predictive Biomarkers for Ovarian Cancer. Diagnostics (Basel). 2021 Mar 7;11(3):465. doi: 10.3390/diagnostics11030465.
citation: Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem. 2012 Jan;60(1):9-21. doi: 10.1369/0022155411428469.